Sebolt-Leopold JS - Search Results

1

ERK activation is required for CCK-mediated pancreatic adaptive growth in mice.

Holtz BJ, Lodewyk KB, Sebolt-Leopold JS, Ernst SA, Williams JA. Holtz BJ, et al. Am J Physiol Gastrointest Liver Physiol. 2014 Oct 1;307(7):G700-10. doi: 10.1152/ajpgi.00163.2014. Epub 2014 Aug 7. Am J Physiol Gastrointest Liver Physiol. 2014. PMID: 25104499 Free PMC article.

2

CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK).

Allen LF, Sebolt-Leopold J, Meyer MB. Allen LF, et al. Semin Oncol. 2003 Oct;30(5 Suppl 16):105-16. doi: 10.1053/j.seminoncol.2003.08.012. Semin Oncol. 2003. PMID: 14613031 Review.

3

Cotargeting MAPK and PI3K signaling with concurrent radiotherapy as a strategy for the treatment of pancreatic cancer.

Williams TM, Flecha AR, Keller P, Ram A, Karnak D, Galbán S, Galbán CJ, Ross BD, Lawrence TS, Rehemtulla A, Sebolt-Leopold J. Williams TM, et al. Mol Cancer Ther. 2012 May;11(5):1193-202. doi: 10.1158/1535-7163.MCT-12-0098. Epub 2012 Mar 12. Mol Cancer Ther. 2012. PMID: 22411900 Free PMC article.

4

MAPK signaling is required for dedifferentiation of acinar cells and development of pancreatic intraepithelial neoplasia in mice.

Collins MA, Yan W, Sebolt-Leopold JS, Pasca di Magliano M. Collins MA, et al. Gastroenterology. 2014 Mar;146(3):822-834.e7. doi: 10.1053/j.gastro.2013.11.052. Epub 2013 Dec 6. Gastroenterology. 2014. PMID: 24315826 Free PMC article.

5

Cyclooxygenase-2 Influences Response to Cotargeting of MEK and CDK4/6 in a Subpopulation of Pancreatic Cancers.

Maust JD, Frankowski-McGregor CL, Bankhead A 3rd, Simeone DM, Sebolt-Leopold JS. Maust JD, et al. Among authors: sebolt leopold js. Mol Cancer Ther. 2018 Dec;17(12):2495-2506. doi: 10.1158/1535-7163.MCT-18-0082. Epub 2018 Sep 25. Mol Cancer Ther. 2018. PMID: 30254182 Free PMC article.

6

Unraveling the complexities of the Raf/MAP kinase pathway for pharmacological intervention.

Herrera R, Sebolt-Leopold JS. Herrera R, et al. Trends Mol Med. 2002;8(4 Suppl):S27-31. doi: 10.1016/s1471-4914(02)02307-9. Trends Mol Med. 2002. PMID: 11927284 Review.

7

MEK inhibitors: a therapeutic approach to targeting the Ras-MAP kinase pathway in tumors.

Sebolt-Leopold JS. Sebolt-Leopold JS. Curr Pharm Des. 2004;10(16):1907-14. doi: 10.2174/1381612043384439. Curr Pharm Des. 2004. PMID: 15180527 Review.

8

Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition.

Ohren JF, Chen H, Pavlovsky A, Whitehead C, Zhang E, Kuffa P, Yan C, McConnell P, Spessard C, Banotai C, Mueller WT, Delaney A, Omer C, Sebolt-Leopold J, Dudley DT, Leung IK, Flamme C, Warmus J, Kaufman M, Barrett S, Tecle H, Hasemann CA. Ohren JF, et al. Nat Struct Mol Biol. 2004 Dec;11(12):1192-7. doi: 10.1038/nsmb859. Epub 2004 Nov 14. Nat Struct Mol Biol. 2004. PMID: 15543157

9

Targeting the mitogen-activated protein kinase cascade to treat cancer.

Sebolt-Leopold JS, Herrera R. Sebolt-Leopold JS, et al. Nat Rev Cancer. 2004 Dec;4(12):937-47. doi: 10.1038/nrc1503. Nat Rev Cancer. 2004. PMID: 15573115 Review.

10

A role for K-ras in conferring resistance to the MEK inhibitor, CI-1040.

Wang Y, Van Becelaere K, Jiang P, Przybranowski S, Omer C, Sebolt-Leopold J. Wang Y, et al. Neoplasia. 2005 Apr;7(4):336-47. doi: 10.1593/neo.04532. Neoplasia. 2005. PMID: 15967111 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

58 results

Search Page